Alpha Cognition Inc. Accumulated Other Comprehensive Income
Alpha Cognition Inc. (ACOG) had Accumulated Other Comprehensive Income of -$104.30 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$104.30K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$104.30K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$104.30K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$104.30K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$104.30K 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$104.30K 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$104.30K 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$104.30K 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$104.30K 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$104.30K 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$104.30K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$104.30K 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$104.30K 10-Q · filed 2024-08-12 |
| 2023-12-31 | -$104.30K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |